share_log

Today's biggest pre-market stock movers: FGI, WKEY, HAPP and more

Benzinga Real-time News ·  Jan 31, 2022 12:22  · Movers

Gainers

  • $FGI Industries(FGI.US)$ rose 47% to $5.53 in pre-market trading after jumping 19% on Friday. The company, last week, priced its IPO at $6 per share.

  • $WISeKey(WKEY.US)$ shares rose 14.5% to $3.72 in pre-market trading. WISeKey reported full year 2021 preliminary results with revenue of $22.2 million.

  • $Happiness Development Group(HAPP.US)$ rose 10.2% to $0.4490 in pre-market trading. Happiness Development Group recently entered into a securities purchase agreement with several non-U.S. strategic investors to sell a total of 12.5 million of its shares.

  • $Cian PLC(CIAN.US)$ rose 8.57% to $7.60 in pre-market trading after jumping around 10% on Friday. Cian recently entered into an agreement for acquisition of SmartDeal.

  • $Knightscope(KSCP.US)$ rose 6.38% to $17.33 in pre-market trading after jumping 175% on Friday. The company, last week, priced its IPO at $10 per share.

  • $Exela Technologies(XELA.US)$ rose 4.86% to $0.66 in pre-market trading after jumping 15% on Friday. Exela Technologies recently announced a share buyback of up to 100 million shares of common stock at $1 per share through an exchange offer of new notes.

  • $Ideanomics(IDEX.US)$ rose 4.07% to $0.950 in pre-market trading.

Losers

  • $Imperial Petroleum(IMPP.US)$ shares fell 26.6% to $1.60 in pre-market trading after jumping 88% on Friday.

  • $Eros STX(ESGC.US)$ shares fell 16.05% to $0.24 in pre-market trading. ErosSTX reported a reverse stock split.

  • $Indonesia Energy(INDO.US)$ shares fell 12.7% to $4.86 in pre-market trading after declining over 5% on Friday.

  • $ObsEva SA(OBSV.US)$ fell 11.5% to $1.39 in pre-market trading after the company issued corporate updates.

  • $Aridis Pharmaceuticals(ARDS.US)$ shares fell 9.2% to $1.78 in pre-market trading. Aridis Pharmaceuticals, last week, announced it received funding to evaluate inhaled monoclonal antibodies to block influenza and SARS-CoV-2 transmission.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
16
Comment Comment · Views 19.8k

Recommended

Write a comment